-
公开(公告)号：US20060088924A1
公开(公告)日：2006-04-27
申请号：US11233581
申请日：2005-09-23
申请人： Jessie English , Thierry Fischmann , Thomas Hesson , Alan Hruza , Weihong Jin , Paul Reichert , Catherine Smith , Shahriar Taremi
发明人： Jessie English , Thierry Fischmann , Thomas Hesson , Alan Hruza , Weihong Jin , Paul Reichert , Catherine Smith , Shahriar Taremi
CPC分类号： C12N9/1205 , C07K2299/00
摘要： The present invention relates to crystals of the ERK2 polypeptide and complexes thereof which are useful, inter alia, for structure assisted drug design.
摘要翻译： 本发明涉及ERK2多肽的结晶及其复合物，其特别用于结构辅助药物设计。
-
公开(公告)号：US20080081360A1
公开(公告)日：2008-04-03
申请号：US11873831
申请日：2007-10-17
申请人： Jessie English , Thierry Fischmann , Thomas Hesson , Alan Hruza , Weihong Jin , Paul Reichert , Catherine Smith , Shahriar Taremi
发明人： Jessie English , Thierry Fischmann , Thomas Hesson , Alan Hruza , Weihong Jin , Paul Reichert , Catherine Smith , Shahriar Taremi
CPC分类号： C12N9/1205 , C07K2299/00
摘要： The present invention relates to crystals of the ERK2 polypeptide and complexes thereof which are useful, inter alia, for structure assisted drug design.
摘要翻译： 本发明涉及ERK2多肽的结晶及其复合物，其特别用于结构辅助药物设计。
-
公开(公告)号：US07722718B2
公开(公告)日：2010-05-25
申请号：US11873831
申请日：2007-10-17
申请人： Jessie English , Thierry Oliver Fischmann , Thomas Hesson , Alan William Hruza , Weihong Jin , Paul Reichert , Catherine Smith , Shahriar Shane Taremi
发明人： Jessie English , Thierry Oliver Fischmann , Thomas Hesson , Alan William Hruza , Weihong Jin , Paul Reichert , Catherine Smith , Shahriar Shane Taremi
CPC分类号： C12N9/1205 , C07K2299/00
摘要： The present invention relates to crystals of the ERK2 polypeptide and complexes thereof which are useful, inter alia, for structure assisted drug design.
摘要翻译： 本发明涉及ERK2多肽的结晶及其复合物，其特别用于结构辅助药物设计。
-
公开(公告)号：US07312061B2
公开(公告)日：2007-12-25
申请号：US11233581
申请日：2005-09-23
申请人： Jessie English , Thierry Oliver Fischmann , Thomas Hesson , Alan William Hruza , Weihong Jin , Paul Reichert , Catherine Smith , Shahriar Shane Taremi
发明人： Jessie English , Thierry Oliver Fischmann , Thomas Hesson , Alan William Hruza , Weihong Jin , Paul Reichert , Catherine Smith , Shahriar Shane Taremi
IPC分类号： C12N9/12
CPC分类号： C12N9/1205 , C07K2299/00
摘要： The present invention relates to crystals of the ERK2 polypeptide and complexes thereof which are useful, inter alia, for structure assisted drug design.
摘要翻译： 本发明涉及ERK2多肽的结晶及其复合物，其特别用于结构辅助药物设计。
-
公开(公告)号：US20100190231A1
公开(公告)日：2010-07-29
申请号：US12754029
申请日：2010-04-05
申请人： JESSIE M. ENGLISH , Thierry Oliver Fischmann , Thomas Hesson , Alan William Hruza , Weihong Jin , Paul Reichert , Catherine Smith , Shahriar Shane Taremi
发明人： JESSIE M. ENGLISH , Thierry Oliver Fischmann , Thomas Hesson , Alan William Hruza , Weihong Jin , Paul Reichert , Catherine Smith , Shahriar Shane Taremi
CPC分类号： C12N9/1205 , C07K2299/00
摘要： The present invention relates to crystals of the ERK2 polypeptide and complexes thereof which are useful, inter alia, for structure assisted drug design.
摘要翻译： 本发明涉及ERK2多肽的结晶及其复合物，其特别用于结构辅助药物设计。
-
6.发明申请Soluble, stable form of HDM2, crystalline forms thereof and methods of use thereof 失效可溶性，稳定形式的HDM2，其结晶形式及其使用方法公开(公告)号：US20050037383A1
公开(公告)日：2005-02-17
申请号：US10822254
申请日：2004-04-09
申请人： Shahriar Taremi , Gaolian Xie , Thomas Hesson , Jose Duca , Corey Strickland , William Windsor , Vincent Madison , Rumin Zhang , Paul Reichert
发明人： Shahriar Taremi , Gaolian Xie , Thomas Hesson , Jose Duca , Corey Strickland , William Windsor , Vincent Madison , Rumin Zhang , Paul Reichert
IPC分类号： C07D209/20 , C07H21/04 , C07K14/47 , C12Q1/68
CPC分类号： C07H21/04 , C07D209/20 , C07K14/47 , C07K2299/00
摘要： The present invention discloses modified Hdm2 proteins that are soluble. In addition, the present invention discloses nucleic acids that encode the modified Hdm2 proteins of the present invention. The invention also provides crystals of modified Hdm2 proteins that are suitable for X-ray crystallization analysis. The present invention also discloses methods of using the modified Hdm2 proteins and crystals thereof to identify, select and/or design compounds that may be used as anticancer agents. The present invention further discloses compounds that bind to modified Hdm2 proteins in protein-ligand complexes.
摘要翻译： 本发明公开了可溶性的修饰的Hdm2蛋白。 此外，本发明公开了编码本发明的修饰的Hdm2蛋白质的核酸。 本发明还提供了适用于X射线结晶分析的修饰的Hdm2蛋白晶体。 本发明还公开了使用修饰的Hdm2蛋白及其晶体鉴定，选择和/或设计可用作抗癌剂的化合物的方法。 本发明还公开了与蛋白质 - 配体复合物中的修饰的Hdm2蛋白结合的化合物。
-
公开(公告)号：US5441734A
公开(公告)日：1995-08-15
申请号：US24330
申请日：1993-02-25
申请人： Paul Reichert , Charles McNemar , Nagamani Nagabhushan , Tattanahalli L. Nagabhushan , Stephen Tindall , Alan Hruza
发明人： Paul Reichert , Charles McNemar , Nagamani Nagabhushan , Tattanahalli L. Nagabhushan , Stephen Tindall , Alan Hruza
IPC分类号： A61K38/00 , A61K38/21 , C07K14/56 , C30B7/00 , C30B28/04 , C30B29/58 , A61K37/66 , A61K9/14 , C07K15/26
CPC分类号： C07K14/56 , A61K38/212 , C30B29/58 , C30B7/00
摘要： The present invention provides for crystalline zinc-interferon alfa-2 (IFN .alpha.-2) having a monoclinic morphology. The present invention further provides for crystalline cobalt-IFN .alpha.-2, crystalline calcium-IFN .alpha.-2, and crystalline IFN .alpha.-2 having a serum half-life of at least about 12 hours when injected into a primate. The present invention further provides for a method for producing a crystalline IFN .alpha.-2 comprising forming a soluble metal-IFN .alpha.-2 complex, and equilibrating the soluble metal-IFN .alpha.-2 complex in solution with an acetate salt of the metal under conditions that will cause the metal-IFN .alpha.-2 solution to become supersaturated and form crystalline metal-IFN .alpha.-2. The present invention also includes crystalline metal-alfa interferon having monoclinic, plate and needle morphologies.
摘要翻译： 本发明提供具有单斜晶形的结晶性锌 - 干扰素α-2（IFNα-2）。 本发明还提供了当注射到灵长类动物中时，具有至少约12小时的血清半衰期的结晶钴-IFFα-2，结晶性钙-IFNα2和结晶IFNα-2。 本发明进一步提供了一种用于产生结晶IFNα-2的方法，包括形成可溶性金属-IFMα-2复合物，并在条件下用金属的乙酸盐平衡溶液中的可溶性金属-IFMα-2复合物 这将导致金属-IFNα-2溶液变得过饱和并形成结晶金属-IFNα-2。 本发明还包括具有单斜晶系，板和针形态的结晶金属-α干扰素。
-
公开(公告)号：US5602232A
公开(公告)日：1997-02-11
申请号：US356021
申请日：1994-12-14
申请人： Paul Reichert , Charles McNemar , Nagamani Nagahhushan , Tattanahalli L. Nagahhushan , Stephen Tindall , Alan Hruza
发明人： Paul Reichert , Charles McNemar , Nagamani Nagahhushan , Tattanahalli L. Nagahhushan , Stephen Tindall , Alan Hruza
CPC分类号： C07K14/56 , A61K38/212 , C30B29/58 , C30B7/00
摘要： A method for producing a crystalline zinc interferon (IFN) .alpha.-2 comprising forming a soluble solution of IFN .alpha.-2 and a metal acetate salt under condtions wherein supersaturation and metal alpha interferon crystals occur.
摘要翻译： 包括在其中发生过饱和和金属α干扰素晶体的条件下形成IFNα-2的可溶性溶液和金属乙酸盐的生产结晶性锌干扰素（IFN）α-2的方法。
-
9.发明授权Soluble, stable form of HDM2, crystalline forms thereof and methods of use thereof 失效可溶性，稳定形式的HDM2，其结晶形式及其使用方法公开(公告)号：US07632920B2
公开(公告)日：2009-12-15
申请号：US10822254
申请日：2004-04-09
申请人： Shahriar Shane Taremi , Gaolian Xie , Thomas Hesson , Jose S. Duca , Corey Strickland , William T. Windsor , Vincent S. Madison , Rumin Zhang , Paul Reichert , Yaolin Wang
发明人： Shahriar Shane Taremi , Gaolian Xie , Thomas Hesson , Jose S. Duca , Corey Strickland , William T. Windsor , Vincent S. Madison , Rumin Zhang , Paul Reichert , Yaolin Wang
CPC分类号： C07H21/04 , C07D209/20 , C07K14/47 , C07K2299/00
摘要： The present invention discloses modified Hdm2 proteins that are soluble. In addition, the present invention discloses nucleic acids that encode the modified Hdm2 proteins of the present invention. The invention also provides crystals of modified Hdm2 proteins that are suitable for X-ray crystallization analysis. The present invention also discloses methods of using the modified Hdm2 proteins and crystals thereof to identify, select and/or design compounds that may be used as anticancer agents. The present invention further discloses compounds that bind to modified Hdm2 proteins in protein-ligand complexes.
摘要翻译： 本发明公开了可溶性的修饰的Hdm2蛋白。 此外，本发明公开了编码本发明的修饰的Hdm2蛋白质的核酸。 本发明还提供了适用于X射线结晶分析的修饰的Hdm2蛋白晶体。 本发明还公开了使用修饰的Hdm2蛋白及其晶体鉴定，选择和/或设计可用作抗癌剂的化合物的方法。 本发明还公开了与蛋白质 - 配体复合物中的修饰的Hdm2蛋白结合的化合物。
-
10.发明授权Polynucleotides encoding soluble, stable forms of human double minute 2 polypeptides 失效编码可溶性，稳定形式的人类双分子2多肽的多核苷酸公开(公告)号：US08034907B2
公开(公告)日：2011-10-11
申请号：US12621241
申请日：2009-11-18
申请人： Shahriar Shane Taremi , Gaolian Xie , Thomas Hesson , Jose S. Duca , Corey Strickland , William T. Windsor , Vincent S. Madison , Rumin Zhang , Paul Reichert , Yaolin Wang
发明人： Shahriar Shane Taremi , Gaolian Xie , Thomas Hesson , Jose S. Duca , Corey Strickland , William T. Windsor , Vincent S. Madison , Rumin Zhang , Paul Reichert , Yaolin Wang
CPC分类号： C07H21/04 , C07D209/20 , C07K14/47 , C07K2299/00
摘要： The present invention discloses modified Hdm2 proteins that are soluble. In addition, the present invention discloses nucleic acids that encode the modified Hdm2 proteins of the present invention. The invention also provides crystals of modified Hdm2 proteins that are suitable for X-ray crystallization analysis. The present invention also discloses methods of using the modified Hdm2 proteins and crystals thereof to identify, select and/or design compounds that may be used as anticancer agents. The present invention further discloses compounds that bind to modified Hdm2 proteins in protein-ligand complexes.
摘要翻译： 本发明公开了可溶性的修饰的Hdm2蛋白。 此外，本发明公开了编码本发明的修饰的Hdm2蛋白质的核酸。 本发明还提供了适用于X射线结晶分析的修饰的Hdm2蛋白晶体。 本发明还公开了使用修饰的Hdm2蛋白及其晶体鉴定，选择和/或设计可用作抗癌剂的化合物的方法。 本发明还公开了与蛋白质 - 配体复合物中的修饰的Hdm2蛋白结合的化合物。
-
-
-
-
-
-
-
-
-
搜索结果
42 条记录 (耗时 0.054 秒)
